ACOR Stock - Acorda Therapeutics, Inc.
Unlock GoAI Insights for ACOR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $117.63M | $118.57M | $129.07M | $152.97M | $192.41M |
| Gross Profit | $71.59M | $88.23M | $88.28M | $119.45M | $157.56M |
| Gross Margin | 60.9% | 74.4% | 68.4% | 78.1% | 81.9% |
| Operating Income | $-23,264,000 | $-42,036,000 | $-77,299,000 | $-86,897,000 | $14.55M |
| Net Income | $-252,854,000 | $-65,916,000 | $-103,954,000 | $-99,594,000 | $-272,965,000 |
| Net Margin | -215.0% | -55.6% | -80.5% | -65.1% | -141.9% |
| EPS | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Visit WebsiteEarnings History & Surprises
ACOREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 31, 2025 | — | — | — | — |
Q4 2024 | Nov 11, 2024 | — | — | — | — |
Q3 2024 | Aug 6, 2024 | — | — | — | — |
Q2 2024 | Apr 1, 2024 | — | $-175.32 | — | — |
Q1 2024 | Mar 7, 2024 | — | $-225.81 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-7.16 | — | — |
Q3 2023 | Aug 8, 2023 | — | $-7.55 | — | — |
Q2 2023 | May 11, 2023 | — | $-13.80 | — | — |
Q1 2023 | Mar 9, 2023 | $-3.00 | $11.40 | +480.0% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-2.00 | $-11.40 | -470.0% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-7.20 | $-55.60 | -672.2% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-7.80 | $-38.60 | -394.9% | ✗ MISS |
Q1 2022 | Mar 9, 2022 | $-22.20 | $-34.60 | -55.9% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-1.56 | $-48.60 | -3015.4% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-41.80 | $-45.80 | -9.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-50.80 | $-49.20 | +3.1% | ✓ BEAT |
Q1 2021 | Mar 4, 2021 | $-29.60 | $-50.00 | -68.9% | ✗ MISS |
Q4 2020 | Nov 3, 2020 | $-35.99 | $-27.59 | +23.3% | ✓ BEAT |
Q3 2020 | Aug 4, 2020 | $-55.19 | $-41.99 | +23.9% | ✓ BEAT |
Q2 2020 | May 5, 2020 | $-41.99 | $-61.19 | -45.7% | ✗ MISS |
Latest News
Frequently Asked Questions about ACOR
What is ACOR's current stock price?
What is the analyst price target for ACOR?
What sector is Acorda Therapeutics, Inc. in?
What is ACOR's market cap?
Does ACOR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ACOR for comparison